Brief: Cipher Pharmaceuticals Acquires Exclusive Canadian Rights To Mob-015 From Moberg Pharma

Moberg Pharma AB (publ)

18/09/2018 12:21

Sept 18 (Reuters) - Cipher Pharmaceuticals Inc  CPH.TO :
    * CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS
TO
MOB-015 FROM MOBERG PHARMA FOR THE TOPICAL TREATMENT OF
ONYCHOMYCOSIS
    * CIPHER PHARMACEUTICALS - MOBERG WILL RECEIVE AN UPFRONT
PAYMENT
OF $0.5 MILLION, ELIGIBLE FOR $14.1 MILLION IN DEVELOPMENT AND
REGULATORY MILESTONES
    * CIPHER PHARMACEUTICALS INC - AGREEMENT ALSO INCLUDES
ROYALTIES
FROM NET PRODUCT SALES IN CANADA
    * CIPHER PHARMACEUTICALS - AGREEMENT PROVIDES MOBERG WILL BE
RESPONSIBLE FOR MANUFACTURING AND SUPPLYING FINISHED PRODUCT TO
CIPHER

Source text for Eikon:  ID:nCNWwWjXxa 
Further company coverage:  CPH.TO 

 ((Reuters.Briefs@thomsonreuters.com;))